Search Results

Juan Jose Fung, Principal Scientist, at GPCR Therapeutics.

, GPCRs, and more RGS proteins and cardiovascular Angiotensin II Signaling: Novel opportunities for therapeutic for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia OMass Therapeutics Releases First Protein Structures in PDB, Advances Lupus Therapy Research Structure Therapeutics Receives

Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic Modalities A quick revision of how β-adrenergic receptors work and how their antagonists can achieve therapeutic Galien USA ‘Best Startup’ Award: Pioneering GPCR-Driven Immunotherapies in Cancer Treatment Structure Therapeutics

Allosteric modulation of conserved motifs and helices in 5HT2BR: Advances drug discovery and therapeutic GPCRs in Cardiology, Endocrinology, and Taste α1-Adrenergic Receptors: Insights into Potential Therapeutic Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics

prediction of first-in-class small molecule agonists for a challenging orphan GPCR for a highly relevant therapeutic

actions and suggest that these discoveries can facilitate new insights into their hallucinogenic and therapeutic

toward exploring the relationship between the actual psychedelic effects and those manifestations of therapeutic

This study examined the therapeutic effect of Ang-(1-7) on secondary injury observed in a murine model

physiological functions and in a large number of Food and Drug Administration (FDA)-approved drugs as therapeutic

only enhances our understanding of class B1 GPCR biology but also opens new avenues for developing therapeutic Graaf, C., et al., Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic

combination of Steyaert’s fundamental research and his ability to apply the research to the development of therapeutic

Stay tuned for our next symposium on GPCRs as Therapeutics Targets on October 11th, 2024. Post-COVID-Vaccination Syndrome With Anti-G-Protein-Coupled Receptor (GPCR) Antibodies Treated With Therapeutic neutrophil biology: inflammation, resolution and beyond Exploring GPCR signaling pathway networks as cancer therapeutic

GHSR1a The growth hormone secretagogue receptor 1a (GHSR1a) is intriguing because of its potential as a therapeutic Initial studies of the receptor focused on the potential therapeutic ability for growth hormone (GH)

These advances have paved the way for development of novel ligands for different therapeutic applications

signaling in humoral immunity Industry News Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics Financial Resultsand Confirms Its 2024 Outlook Sosei Heptares officially changed their name to Nxera Domain Therapeutics

2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic

From omics to epigenetics The impact of nanobodies on GPCR structural biology and their potential as therapeutic complexes with MolBoolean Screening GPR75 Modulators Using Medium-Throughput Reporter Gene Assay GPCR Therapeutics

stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics

animals and opens the way to remotely controlling dopaminergic neurotransmission for fundamental and therapeutic

Finally, we briefly discuss the therapeutic targeting of vGPCRs as future treatment of acute and chronic

These can be used either as stand-alone therapeutics or to improve the safety profile of opioid drugs

new insight into how EBI2 is activated by an oxysterol ligand and will facilitate the development of therapeutic

receptor subfamily, CX3CR1 binds to its sole endogenous ligand CX3CL1, which shows notable potential as a therapeutic

using unique tools, and thus establishes a foundation for the development of fine-tuned aGPCR-targeted therapeutics

Therapeutic potential of opioid receptor heteromers in chronic pain and associated comorbidities. Industry News Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover SMILES-based de novo molecular generation with curriculum and deep reinforcement learning Structure Therapeutics

clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics

Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides sustained pain relief. Patients with Idiopathic Pulmonary Fibrosis Exscientia Business Update for First Quarter 2023 Structure Therapeutics

In summary, targeting GPCR-activated ERK pathways represents a promising strategy for developing new therapeutics ERK-dependent apoptosis as a potential therapeutic strategy for cancer. Cells, 10(10), 2509.